0001104659-14-012684.txt : 20140224 0001104659-14-012684.hdr.sgml : 20140224 20140224152046 ACCESSION NUMBER: 0001104659-14-012684 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20140224 DATE AS OF CHANGE: 20140224 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Egalet Corp CENTRAL INDEX KEY: 0001586105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463575334 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87969 FILM NUMBER: 14636685 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DRIVE STREET 2: SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-875-3095 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DRIVE STREET 2: SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SUNSTONE LIFE SCIENCE VENTURES FUND II K/S CENTRAL INDEX KEY: 0001591179 IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: LAUTRUPSGADE 7, 5 CITY: COPENHAGEN O STATE: G7 ZIP: DK-2100 BUSINESS PHONE: 45-2012-6000 MAIL ADDRESS: STREET 1: LAUTRUPSGADE 7, 5 CITY: COPENHAGEN O STATE: G7 ZIP: DK-2100 SC 13G 1 a14-6458_3sc13g.htm SC 13G

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No.     )*

 

Egalet Corporation

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

28226B104

(CUSIP Number)

February 11, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

x

Rule 13d-1(c)

o

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

CUSIP No. 28226B104

13G

 

 

 

1.

Names of Reporting Persons
Sunstone Life Science Ventures Fund II K/S

 

 

2.

Check the Appropriate Box if a Member of a Group

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Denmark

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

5.

Sole Voting Power
1,859,615 shares of Common Stock of the Issuer

 

6.

Shared Voting Power
0

 

7.

Sole Dispositive Power
1,859,615 shares of Common Stock of the Issuer

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
1,859,615 shares of Common Stock of the Issuer

 

 

10.

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares   o

 

 

11.

Percent of Class Represented by Amount in Row (9)
12.2%

 

 

12.

Type of Reporting Person
CO

 

2


 

CUSIP No. 28226B104

13G

 

 

SCHEDULE 13G

 

Item 1(a).

Name of Issuer:
Egalet Corporation

Item 1(b).

Address of Issuer’s Principal Executive Offices:
460 East Swedesford Road, Suite 1050

Wayne, Pennsylvania 19087

Item 2 (a).

Name of Person Filing:
Sunstone Life Science Ventures Fund II K/S

Item 2(b).

Address of Principal Business Office:
Lautrupsgade 7, 5th Floor

Copenhagen O, Denmark DK-2100

Item 2(c).

Citizenship:
Denmark

Item 2(d).

Title of Class of Securities:
Common Stock, par value $0.001

Item 2(e)

CUSIP Number:
28226B104

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not Applicable.

 

Item 4.

Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount beneficially owned:
1,859,615 shares of Common Stock of the Issuer

 

(b)

Percent of class: 12.2%.
Such percentage is based upon 15,257,503 outstanding shares of Common Stock of the Issuer as of February 11, 2014.

 

(c)

Number of shares as to which such person has:

 

 

 

(i)

Sole power to vote or to direct the vote:

1,859,615

 

 

(ii)

Shared power to vote or to direct the vote:

0

 

 

(iii)

Sole power to dispose or to direct the disposition of:

1,859,615

 

 

(iv)

Shared power to dispose or to direct the disposition of:

0

 

3


 

CUSIP No. 28226B104

13G

 

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not Applicable.

 

 

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

4


 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:  February 24, 2014

 

 

 

 

SUNSTONE LIFE SCIENCE VENTURES FUND II K/S,

 

acting through its general partner Sunstone LSV General

 

Partner II ApS

 

 

 

 

 

By:

/s/ Søren Lemonius

 

 

Name: Søren Lemonius

 

 

Title:   Partner

 

 

 

 

 

By:

/s/ Merete Lundbye Møller

 

 

Name:  Merete Lundbye Møller

 

 

Title:    Partner

 

5